S-B. Kim

LBA8_PR Pembrolizumab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced esophageal cancer: The phase 3 KEYNOTE-590 study

Ken Kato, J-M. Sun, Manan Shah et al. · Annals of Oncology · 2020 · 131 citations

Medicine, Oncology, Pharmacology +9

Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial

Yeon Hee Park, Tae‐Yong Kim, Gun Min Kim et al. · The Lancet Oncology · 2019 · 130 citations

Medicine, Oncology, Pharmacology +16

Comparison of mammography, sonography, MRI and clinical examination in patients with locally advanced or inflammatory breast cancer who underwent neoadjuvant chemotherapy

Hee Jung Shin, Hyun‐Ha Kim, J.-H Ahn et al. · British Journal of Radiology · 2011 · 117 citations

Medicine, Oncology, Pathology +17

LBA1 Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (Pts) with HER2+ metastatic breast cancer (mBC): Results of the randomized phase III DESTINY-Breast03 study

Javier Cortés, S-B. Kim, W-P. Chung et al. · Annals of Oncology · 2021 · 96 citations · Full text

Medicine, Oncology, Pharmacology +17

Abstract S1-03: Primary results from BETH, a phase 3 controlled study of adjuvant chemotherapy and trastuzumab ± bevacizumab in patients with HER2-positive, node-positive or high risk node-negative breast cancer

DJ Slamon, SM Swain, Marc Buyse et al. · Cancer Research · 2013 · 92 citations

Medicine, Oncology, Pharmacology +17